Nadroparin

ApprovedSmall molecule

GSK

Nadroparin is one of 176 small molecule programs targeting Venous Thromboembolism. It is currently in Approved.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

ThromboembolismActive, not recruiting

Deep Vein ThrombosisActive, not recruiting

Prostate CancerActive, not recruiting

COVID-19Active, not recruiting

Subarachnoid HemorrhageActive, not recruiting

Knee InjuryActive, not recruiting

Ischemic StrokeActive, not recruiting

Venous ThromboembolismApproved

Active, not recruiting

ThromboembolismApproved

Active, not recruiting

Deep Vein ThrombosisPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Knee InjuryPhase 3

Active, not recruiting

Ischemic StrokeApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Nadroparin

GSK

Approved

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Stivarga

Bayer

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Benadryl

PParkedale

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Subarachnoid Hemorrhage

NCT04507178

Clinical

Trials by Indication[1]

Anticoagulation2 trials

LMWH Infusion as Anticoagulation for Home HD

Unknown status·—·Phase 4·NCT02957877·12 enrolled

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04066764·200 enrolled

Venous Thromboembolism2 trials

Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

Completed·MMartini Hospital Groningen·Phase 3·NCT01431456·148 enrolled

Prophylaxis of Venous Thromboembolism After Bariatric Surgery

Unknown status·RRijnstate Hospital·Phase 4·NCT02295150·50 enrolled

Thromboembolism1 trial

Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

Completed·—·Phase 4·NCT00796692·274 enrolled

Palliative Care1 trial

Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care

Terminated·UUniversity Hospital, Geneva··NCT00303407

Safety and Efficacy1 trial

Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration

Completed·OOnze Lieve Vrouwe Gasthuis·Phase 4·NCT00286273·215 enrolled

9 more indications

Knee Injury1 trial

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

Completed· GSK logo

GSK·Phase 3·NCT00843492·1,351 enrolled

Ischemic stroke1 trial

Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke

Unknown status·UUniversity Hospital, Martin·Phase 4·NCT01862978·150 enrolled

Refractory1 trial

Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

Not yet recruiting·SShanghai Zhongshan Hospital·N/A·NCT06319131·84 enrolled

Complication1 trial

Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures

Unknown status·—·Phase 2/3·NCT00881088·669 enrolled

Deep Vein Thrombosis1 trial

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04067505·224 enrolled

Prostate Cancer1 trial

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

Completed· GSK logo

GSK·Phase 3·NCT00312013·503 enrolled

COVID-191 trial

Nadroparin Pharmacokinetics in Different Stages of COVID-19

Completed·MMedical University of Lublin··NCT05621915·43 enrolled

Low Molecular Weight Heparin1 trial

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

Completed·CClinique Saint Pierre Ottignies·Phase 4·NCT04982055·60 enrolled

Subarachnoid Hemorrhage1 trial

Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine

Recruiting·—·Phase 2·NCT04507178·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Nadroparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nadroparin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nadroparin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Nadroparin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Anticoagulation2 trials

Venous Thromboembolism2 trials

Thromboembolism1 trial

Palliative Care1 trial

Safety and Efficacy1 trial

Knee Injury1 trial

Ischemic stroke1 trial

Refractory1 trial

Complication1 trial

Deep Vein Thrombosis1 trial

Prostate Cancer1 trial

COVID-191 trial

Low Molecular Weight Heparin1 trial

Subarachnoid Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News